Bionano Revenue Declines as OGM Adoption Progresses
Event summary
- Bionano Genomics reported preliminary Q4 2025 revenue between $7.8M and $8.0M, a 2-4% year-over-year decrease.
- Full-year 2025 revenue is projected at $28.4M to $28.6M, down 7-8% year-over-year.
- The company installed 9 new OGM systems in Q4 and 32 for the full year, bringing the total installed base to 387.
- Bionano secured a second Category I CPT code for OGM use in constitutional genetic disorders, with a 47% increase in payment determination for hematologic malignancies.
The big picture
While Bionano highlights progress in reimbursement and software upgrades, the revenue decline signals challenges in driving widespread OGM adoption. The company’s strategic shift towards routine users appears to be underway, but the financial results suggest this transition is not yet translating into significant growth. The long-term viability of Bionano hinges on demonstrating the clinical and economic value of OGM to a broader customer base.
What we're watching
- Financial Trajectory
- Whether Bionano can reverse the year-over-year revenue decline and achieve sustained growth will depend on accelerating OGM adoption and expanding reimbursement coverage.
- CPT Code Impact
- The full impact of the second Category I CPT code on revenue generation and adoption rates remains to be seen and will be a key indicator of future success.
- Competitive Landscape
- The pace at which competitors develop and deploy alternative genomic analysis solutions will influence Bionano’s ability to maintain its market position and pricing power.
Related topics